Celgene Corporation to Present at JMP Securities Healthcare Focus Conference and Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS’ National Coverage Determination on ESAs
Celgene Corporation to Present at JMP Securities Healthcare Focus Conference and Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS’ National Coverage Determination on ESAs
City of Industry, CA –(www.FinancialNewsUSA.com)– 11/09/2007 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Celgene Corporation (NASDAQ: CELG) announced recently that its presentation at the JMP Securities Healthcare Focus Conference on Tuesday, November 13, 2007 at 9:00 am EST will be webcast live and will be available in the investor relations section of the Company’s website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
CV Therapeutics, Inc. (NASDAQ: CVTX) announced recently that data from a preclinical study of the selective adenosine A1 agonist tecadenoson, in combination with a low dose of the beta blocker metoprolol, showed increased rate control compared to either agent alone (p
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Leave a comment